Relmada Therapeutics Inc logo

Relmada Therapeutics Inc

NEW
NAS:RLMD (USA)  
$ 0.37 -0.003 (-0.81%) 11:08 PM EST
At Loss
P/B:
0.23
Market Cap:
$ 11.07M
Enterprise V:
$ -42.95M
Volume:
858.30K
Avg Vol (2M):
969.86K
Trade In:
Volume:
858.30K
At Loss
Avg Vol (2M):
969.86K

Business Description

Description
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.86
Interest Coverage No Debt
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.89
Quick Ratio 6.89
Cash Ratio 6.69

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -22.6
Name Current Vs Industry Vs History
ROE % -117.75
ROA % -103.49
ROIC % -5922.52
3-Year ROIIC % -3759.91
ROCE % -124.77

Financials (Next Earnings Date:2025-03-19 Est.)

RLMD's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:RLMD

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Relmada Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -2.86
Beta -0.1
3-Year Sharpe Ratio -0.01
3-Year Sortino Ratio -0.01
Volatility % 105.77
14-Day RSI 16
14-Day ATR ($) 0.262074
20-Day SMA ($) 1.92564
12-1 Month Momentum % 28.4
52-Week Range ($) 0.35 - 7.2225
Shares Outstanding (Mil) 30.17

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Relmada Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Relmada Therapeutics Inc Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Relmada Therapeutics Inc Frequently Asked Questions

What is Relmada Therapeutics Inc(RLMD)'s stock price today?
The current price of RLMD is $0.37. The 52 week high of RLMD is $7.22 and 52 week low is $0.35.
When is next earnings date of Relmada Therapeutics Inc(RLMD)?
The next earnings date of Relmada Therapeutics Inc(RLMD) is 2025-03-19 Est..
Does Relmada Therapeutics Inc(RLMD) pay dividends? If so, how much?
Relmada Therapeutics Inc(RLMD) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1